Q-omics provides the consensus-scored ETV1 profile across patient tissues and cancer cell-line models. ETV1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, ETV1 is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, ETV1 protein abundance shows 21,979 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, LUAD, and GBM as cancer lineages where ETV1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ETV1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ETV1 survival associations across molecular data types. ETV1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ETV1 RNA expression–survival associations across cancer types. High ETV1 expression shows unfavorable associations in LIHC, ACC, STAD and BLCA, but favorable associations in HNSC and LGG. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for ETV1 RNA expression.
This table summarizes ETV1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in LUAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ETV1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ETV1 shows lower tumor expression in LUAD, LUSC, BRCA and KICH and higher tumor expression in THCA and CHOL. The LUAD box plot shows higher ETV1 RNA expression in normal versus tumor tissue (log2 FC = −1.577, t-test p < 0.001).
This table shows molecular features associated with ETV1 in patient tissues and cancer cell lines. In patient samples, ETV1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ETV1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
